Clinical Trials Browser

Completed × Interventional × olaparib × Clear all

NCT03462342 2026-03-17

CAPRI

Phase 2 Completed

High Grade Serous Carcinoma

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02787642 2026-02-25

RADIOSARP

Phase 1 Completed

41 enrolled 15 charts

Sarcoma

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1/2 Completed

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Phase 1 Completed

Rhabdomyosarcoma, Sarcoma, Ewing

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Completed

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT05240898 2025-12-18

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT03109080 2025-11-24

RadioPARP

Phase 1 Completed

Radiation Injuries, Triple Negative Breast Neoplasms

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1 Completed

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02755844 2025-10-02

ENDOLA

Phase 1/2 Completed

Endometrial Neoplasms

NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Phase 2 Completed

36 enrolled 14 charts

Castration-Resistant Prostate Carcinoma

NCT03561870 2025-09-12

OLAGLI

Phase 2 Completed

Glioma, Recurrence

NCT04076579 2025-08-29

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Phase 2 Completed

29 enrolled 13 charts

Sarcoma

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Phase 2 Completed

298 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05005728 2025-07-17

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT05320757 2025-06-11

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Phase EARLY_PHASE1 Completed

Endometrial Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Phase 1 Completed

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT04236414 2025-04-04

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Phase 1 Completed

Neoplasms

NCT04306367 2025-02-17

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT03532880 2025-02-07

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1 Completed

Small Cell Lung Carcinoma

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

6 enrolled 12 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03745950 2024-12-04

UTOLA

Phase 2 Completed

Endometrial Neoplasms

NCT03838744 2024-12-04

TOMAS2

Phase 2 Completed

Sarcoma

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03378297 2024-10-30

IMPACT

Phase EARLY_PHASE1 Completed

Ovarian Neoplasms

NCT04456699 2024-10-29

LYNK-003

Phase 3 Completed

335 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

NCT03205761 2024-10-18

COMETABreast

Phase 2 Completed

11 enrolled 20 charts

Advanced Breast Cancer

NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

24 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

Advanced Cancer

NCT05700669 2024-09-19

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Phase 1/2 Completed

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Ovarian Neoplasms

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03127215 2024-05-08

NCT-PMO-1603

Phase 2 Completed

Cancers With DNA Repair-Deficiency

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Phase 1 Completed

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03117933 2024-01-23

OCTOVA

Phase 2 Completed

Ovarian Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

Phase 2 Completed

54 enrolled 17 charts

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

NCT00782574 2023-12-21

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT03448718 2023-11-22

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Phase 2 Completed

19 enrolled 9 charts

Metastatic Urothelial Cancer

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Phase 2 Completed

158 enrolled 32 charts

Prostatic Neoplasms